Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.62 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20343824 | 0.90 | ADORA2A (0.60) | ADORA2AADORA1TMIGD3ADORA2BPDE4A | |
| SCHEMBL7206049 | 0.83 | ADORA2A (0.68) | ADORA2AADORA1TMIGD3ADORA2BTLR7 | |
| SCHEMBL2913215 | 0.82 | ADORA2A (0.67) | ADORA2AADORA1TMIGD3ADORA2BTLR7 | |
| SCHEMBL5732024 | 0.81 | ADORA2A (0.65) | ADORA2AADORA1TMIGD3ADORA2BTLR7 | |
| SCHEMBL7210349 | 0.79 | ADORA2A (0.62) | ADORA2AADORA1TMIGD3ADORA2BTLR7 | |
| SCHEMBL7208425 | 0.78 | ADORA2A (0.76) | ADORA2AADORA1TMIGD3ADORA2BTLR7 | |
| SCHEMBL7205701 | 0.78 | ADORA2A (0.61) | ADORA2AADORA1TMIGD3ADORA2BTLR7 | |
| SCHEMBL7211527 | 0.78 | ADORA2A (0.62) | ADORA2AADORA1TMIGD3ADORA2BTLR7 | |
| SCHEMBL7204696 | 0.78 | ADORA2A (0.61) | ADORA2AADORA1TMIGD3ADORA2BTLR7 | |
| SCHEMBL7210266 | 0.78 | ADORA2A (0.61) | ADORA2AADORA1TMIGD3ADORA2BTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-11-28 | — | — | US | disclosed |
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-05-07 | — | — | US | disclosed |
| EP-2776439-B1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-04 | — | — | EP | disclosed |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-05 | — | — | US | disclosed |
| US-9556176-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-9556176-B2 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2017-01-31 | — | — | US | disclosed |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2014-10-30 | — | — | US | disclosed |
| WO-2013068438-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN R&D IRELAND (IE) | 2013-05-16 | — | — | WO | disclosed |
| US-7642350-B2 | Purine derivatives | PFIZER LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642350-B2 | Purine derivatives | PFIZER LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642350-B2 | Purine derivatives | PFIZER LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| CN-101203519-A | 2-amido-6-amino-8-oxopurine derivatives as Toll-like receptor modulators for the treatment of cancer and viral infections such as hepatitis c | PFIZER LTD (GB) | 2008-06-18 | — | — | CN | disclosed |
| EP-1888587-A1 | 2-AMIDO-6-AMINO-8-OXOPURINE DERIVATIVES AS TOLL-LIKE RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS, SUCH AS HEPATITIS C | Pfizer Limited (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264448-A1 | Purine derivatives | PFIZER LIMITED | 2006-11-23 | — | — | US | disclosed |
| WO-2006117670-A1 | 2-AMIDO-6-AMINO-8-OXOPURINE DERIVATIVES AS TOLL-LIKE RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS, SUCH AS HEPATITIS C | PFIZER LIMITED (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280167-B2 | Purine derivatives for the treatment of viral infections | PNP, ADA, HPRT1 | ADORA2A 14/4885ADORA1 37/4885TMIGD3 2446/4885 |
| US-20140323441-A1 | Purine derivatives for the treatment of viral infections | PNP, HPRT1, TYMP | ADORA2A 17/4885ADORA1 28/4885TMIGD3 2946/4885 |
| US-20060264448-A1 | Purine derivatives | TLR9, TLR7, TLR1 | ADORA2A 7/4885ADORA1 9/4885TMIGD3 1167/4885 |
| US-20170283419-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | ADORA2A 14/4885ADORA1 37/4885TMIGD3 2446/4885 |
| US-20190359614-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, ADA, HPRT1 | ADORA2A 14/4885ADORA1 37/4885TMIGD3 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.